News | June 05, 2023
Briefs: Ipca Laboratories, Lupin and Zydus
The company has extended its full co-operation and support to the officials of the Income Tax Department
The company has extended its full co-operation and support to the officials of the Income Tax Department
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The appointment is effective from May 01, 2023 for five years
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
The acquisition is for an enterprise value of Rs. 218 crores
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
The company will address the observations within a stipulated timeline working with the regulators
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
Subscribe To Our Newsletter & Stay Updated
